Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

J&J strengthens heart device business with $13.1 billion Shockwave acquisition

Reading Time: < 1 minute

Johnson & Johnson (J&J) has made a significant move in the medical devices industry by agreeing to acquire Shockwave Medical in a deal valued at $13.1 billion. This acquisition is part of J&J’s strategy to strengthen its cardiac-health-centric business and drive growth in the market.

The deal, which includes debt, sees J&J offering $335 per share in cash, totaling $12.5 billion for the equity portion. This offer represents a 17% premium to Shockwave’s stock price in late March, showcasing J&J’s strong interest in the company.

Shockwave Medical specializes in a device that uses shockwaves to break down calcified plaque in heart vessels, a revolutionary treatment similar to how kidney stones are treated. With the total addressable market for such therapies estimated at around $10 billion, this acquisition opens up new opportunities for J&J in the cardiac health sector.

This move follows J&J’s recent acquisitions in the cardiac health division, including the purchase of heart pump maker Abiomed and heart-centric device maker Laminar. J&J CEO Joaquin Duato expressed confidence in the Shockwave acquisition, stating that it aligns with the company’s focus on enhancing its cardiovascular product portfolio.

As J&J prepares to face competition for its blockbuster drug Stelara, the company is looking to strengthen its medical devices business. Analysts view this acquisition as a strategic move by J&J to tap into a lucrative market and drive revenue growth.

With Shockwave’s catheter-based treatment generating significant product sales, J&J expects to finance the deal through a combination of cash and debt. Despite a projected decrease in adjusted earnings per share this year, J&J remains optimistic about the long-term benefits of this acquisition.

Taylor Swifts New Album Release Health issues from using ACs Boston Marathon 2024 15 Practical Ways To Save Money